Risk factors
Crinetics Pharmaceuticals (CRNX) risk factors
Item 1A of every Crinetics Pharmaceuticals, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors67 risks6 new19 dropped22 reworded
Crinetics transitioned to a commercial-stage company following FDA approval of PALSONIFY for acromegaly in September 2025. Financial success now heavily relies on successfully launching and commercializing PALSONIFY and advancing pipeline assets like atumelnant. The company faces ongoing reliance on third-party manufacturers without redundant supply arrangements for key raw materials.
Filed Feb 26, 2026 - FY2024 10-K risk factors80 risks
Crinetics is a clinical-stage biopharmaceutical company developing paltusotine and atumelnant for rare endocrine diseases and tumors.
Filed Feb 27, 2025